StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) income statement

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$70.75−0.31 (-0.44%)

Close on Nov 18, 2026Market cap $474.89MP/E –Yield –

Monopar Therapeutics income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-14.2%

Financial strength

Current ratio
33.56
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1313.7%

Valuation

P/E ratio
–
Price to sales
–
Price to book
3.63
Dividend yield
–

See a number that looks wrong?